Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
FDA approval of AMDS is a major near-term catalyst, with added portfolio upside from the Endospan acquisition. Q1 2026 revenue rose 18% YoY and adjusted EBITDA rose 26%, while the stock gained about 21% over 21 trading days and closed at a fresh short-term high on 2026-07-28.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Higher trend ⢠Breakout failure ⢠Range compression Support Level: $24.90-$25.00 Resistance Level: $25.40-$25.70 Over the last month, AORT has trended higher and is holding near its range highs, but repeated stalls under $25.4-$25.7 mean the bullish move still needs a decisive breakout to confirm.
Sentiment & News
Key News Insights: ⢠FDA Approval ⢠Growth Catalyst ⢠Earnings Ahead Artivion's FDA approval for AMDS removes a major adoption barrier and strengthens the case for growth, with rising institutional interest and Q2 results next on deck.
AI Summary
AORT has shifted from a pure product-catalyst story to an execution test: it is growing profitably with strong margins and double-digit revenue gains, but at ~100x earnings the stock only works if AMDS adoption and Endospan integration quickly convert regulatory wins into durable commercial traction, or else the multiple could compress fast.
Description
Artivion Inc. develops, manufactures and distributes medical devices and implantable human tissues for cardiac, vascular, thoracic and general surgical procedures worldwide. Its portfolio combines biologic materials, synthetic vascular grafts, surgical sealants, hemostatic agents, prosthetic heart valves and a range of endovascular stent graft systems and preservation and coating services for device makers. The company serves hospitals and surgeons, was founded in 1984, and changed its name from CryoLife, Inc. to Artivion Inc. in January 2022, with headquarters in Kennesaw, Georgia.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 28 | Aug 4 | AORT | Artivion, Inc. | FDA approval of AMDS is a major near-term catalyst, with added portfolio upside from the Endospan acquisition. Q1 2026 revenue rose 18% YoY and adjusted EBITDA rose 26%, while the stock gained about 21% over 21 trading days and closed at a fresh short-term high on 2026-07-28. | Active | +2.5% |
| Jul 21 | Jul 28 | AORT | Artivion, Inc. | Catalyst-rich medtech setup with Q1 2026 revenue up 18% YoY, adjusted EBITDA up 26%, FDA PMA approval for NEXUS, acquisition of Endospan, and FDA PMA approval for AMDS Hybrid Prosthesis on 2026-06-29 opening an estimated $150M U.S. market. | Closed | +8.3% |
| Jul 14 | Jul 21 | AORT | Artivion, Inc. | Recent medical-device catalyst: FDA approved AMDS Hybrid Prosthesis on 2026-06-29, expanding the U.S. commercial path, and the Endospan acquisition closed on 2026-05-18. Q1 2026 revenue rose 18% YoY and the stock is up about 14.8% over 21 trading days. | Closed | +7.8% |
| Jul 6 | Jul 13 | AORT | Artivion, Inc. | Recent regulatory catalysts are substantial: FDA PMA approval for NEXUS on 2026-04-07, Endospan acquisition completion on 2026-05-18, and FDA approval of AMDS on 2026-06-29. AMDS opens an estimated $150M annual U.S. market, and the stock is up about 18% over 21 trading days. | Closed | -2.5% |
| Jun 29 | Jul 6 | AORT | Artivion, Inc. | Fresh medical-device catalyst with improving operations: AORT received FDA PMA approval for AMDS Hybrid Prosthesis on 2026-06-29 after prior NEXUS Aortic Arch approval on 2026-04-07 and Endospan acquisition completion on 2026-05-18; Q1 2026 revenue rose 18% YoY to $116.3M and adjusted EBITDA rose 26% to $22.1M. | Closed | +10.1% |